Loading...
OTCM
AXRX
Market cap16kUSD
Jun 06, Last price  
0.00USD
Name

Amexdrug Corp

Chart & Performance

D1W1MN
P/E
0.47
P/S
0.00
EPS
0.00
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
4m
3,915,256
Net income
36k
35,833
CFO

Profile

Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products. It is also involved in the research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices. The company operates in two segments, Distribution and Health and Beauty Products. In addition, it engages in the distribution of prescription and over-the-counter drugs, non-drug products, and health and beauty products; and private manufacturing and labeling activities. Further, the company manufactures and sells facial and body creams, arthritic pain relief medications, and hair and nail care products to pharmacies, beauty salons, beauty supply stores, and other fine shops. Amexdrug Corporation markets its products under the Sponix name. The company distributes its products through its subsidiaries primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities, and other wholesalers and retailers in the state of California. The company was formerly known as Harlyn Products, Inc. and changed its name to Amexdrug Corporation in April 2000 to reflect the change in its business to the sale of pharmaceutical products. Amexdrug Corporation was founded in 1963 and is based in Commerce, California.
IPO date
Jul 21, 1972
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FY
2023‑12
Income
Revenues
3,915
 
Cost of revenue
2,880
Unusual Expense (Income)
NOPBT
1,035
NOPBT Margin
26.43%
Operating Taxes
(168)
Tax Rate
NOPAT
1,203
Net income
36
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1
Long-term debt
490
Deferred revenue
Other long-term liabilities
Net debt
(821)
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
1,313
Long term investments
Excess cash
1,117
Stockholders' equity
1,753
Invested Capital
1,128
ROIC
106.67%
ROCE
46.11%
EV
Common stock shares outstanding
169,410
Price
Market cap
EV
EBITDA
1,035
EV/EBITDA
Interest
81
Interest/NOPBT
7.85%